Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has unveiled its first program targeting Type 1 diabetes, introducing an engineered cell therapy designed to restore natural insulin production without the …
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes Read More